Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Innoviva Inc    INVA

INNOVIVA INC (INVA)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/14/2017 11/15/2017 11/16/2017 11/17/2017 11/20/2017 Date
12.78(c) 12.99(c) 12.97(c) 13.06(c) 13.23 Last
755 129 648 640 1 173 048 637 047 343 349 Volume
+1.43% +1.64% -0.15% +0.69% +1.30% Change
More quotes
Financials ($)
Sales 2017 216 M
EBIT 2017 178 M
Net income 2017 129 M
Debt 2017 366 M
Yield 2017 2,55%
Sales 2018 277 M
EBIT 2018 249 M
Net income 2018 236 M
Debt 2018 164 M
Yield 2018 2,55%
P/E ratio 2017 11,58
P/E ratio 2018 6,28
EV / Sales2017 8,22x
EV / Sales2018 5,68x
Capitalization 1 411 M
More Financials
Company
Innoviva, Inc. engages in the development, commercialization, and financial management of bio-pharmaceuticals.Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone... 
Sector
Pharmaceuticals
Calendar
02/08Earnings Release
More about the company
Surperformance© ratings of Innoviva Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on INNOVIVA INC
11/17 INNOVIVA : GSK, Innovivas Trelegy Ellipta cleared for COPD
11/16 Europe approves GlaxoSmithKline's new triple lung drug
11/06 GLAXOSMITHKLINE : GSK study demonstrates superiority of Anoro Ellipta to Stiolto..
11/03 INNOVIVA : Management's Discussion and Analysis of Financial Condition and Resul..
11/01 INNOVIVA : to Participate at the Credit Suisse and Stifel Annual Healthcare Conf..
11/01DJGlaxoSmithKline Receives Positive Data for Anoro Ellipta Treatment
10/25 INNOVIVA : misses 3Q profit forecasts
10/25 INNOVIVA, INC. : Results of Operations and Financial Condition, Financial Statem..
10/25 INNOVIVA : Reports Third Quarter 2017 Financial Results and Provides Business Up..
10/18 INNOVIVA TO REPORT THIRD QUARTER FIN : 00 p.m. EDT
More news
Sector news : Pharmaceuticals - NEC
05:58p FTSE recoups early losses as cyclicals recover
02:50pDJSHIRE : Appoints Thomas Dittrich as Chief Financial Officer
02:16pDJSHIRE PLC SHIRE PLC : Directorate Change
12:24pDJROCHE : Shares Rise on Positive Results From Clinical Trials
08:19aDJNOVARTIS : Secures EU Approval for Tasigna Treatment in Children
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09:06a Premarket analyst action - healthcare
11/16 Innoviva (INVA) Presents At Stifel 2017 Healthcare Conference - Slideshow
11/16 Glaxo's inhaled triplet therapy for COPD OK'd in Europe
10/25 Innoviva's (INVA) CEO Michael Aguiar on Q3 2017 Results - Earnings Call Trans..
10/25 Innoviva EPS in-line, misses on revenue
Chart INNOVIVA INC
Duration : Period :
Innoviva Inc Technical Analysis Chart | INVA | US45781M1018 | 4-Traders
Technical analysis trends INNOVIVA INC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 13,0 $
Spread / Average Target -0,46%
EPS Revisions
Managers
NameTitle
Michael W. Aguiar President, Chief Executive Officer & Director
William H. Waltrip Chairman
Eric d'Esparbes Chief Financial Officer & Senior Vice President
Theodore L. Witek Chief Scientific Officer & Senior Vice President
Catherine J. Friedman Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INNOVIVA INC22.06%1 411
JOHNSON & JOHNSON19.78%370 740
NOVARTIS11.20%219 321
PFIZER8.90%210 830
ROCHE HOLDING LTD.-1.55%200 193
MERCK AND COMPANY-6.23%150 550